NEW YORK (GenomeWeb News) – London Genetics and Diaceutics today announced a partnership to develop software tools to provide pharmaceutical companies with access to academic biomarker research groups.
The software will be based on the Diaceutics' Fusion platform, a series of proprietary web applications, and London Genetics' Biomarker Pathway platform.
Terms of the deal were not announced.
The software, which is anticipated to be launched next year, will allow research teams to build biomarker hypotheses, request expressions of interest, and prepare proposals for clinical development, the two firms said in a joint statement. The expressions of interest, as well as access to patient samples and investigator networks, will be sent to academic research teams, enabling partners to identify and being collaborative projects.
"The new tools will enable commercial biomarker research teams to comprehensively explore global biomarker resources to identify genes and gene sequences, as well as the researchers and clinicians relevant to their targeted therapy research," the companies said.
In a statement, Peter Keeling, CEO of Diaceutics, said that biomarker research has been hampered by a lack of awareness among researchers of "the capabilities of external research centers," resulting in missed opportunities for collaborations. The partnership, he said, will address a "key problem for therapy development teams."
London Genetics is a not-for-profit company formed in 2007 to promote the use of pharmacogenetics. Diaceutics, which has offices in Washington, DC, and the UK, is a consulting firm specializing in personalized medicine.